Impaired wound healing compositions and treatments
View Patent ↗Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.
1. A method of treating a subject having a wound not healing at an expected rate, which comprises administration of an effective amount of an article of manufacture comprising an anticonnexin 43 polynucleotide present at a concentration from 1.0 to about 40.0 milligrams per milliliter to the wound.
2. A method according to claim 1 wherein the anticonnexin 43 polynucleotide is selected from the group consisting of a connexin 43 antisense polynucleotide, an RNAi polynucleotide, and an siRNA polynucleotide.
3. A method according to claim 1 wherein the anticonnexin 43 polynucleotide is administered for at least about 0.5 hours, at least about 1-2 hours, at least about 2-4 hours, at least about 4-6 hours, or at least about 6-8 hours.
4. A method according to claim 1 wherein the wound is selected from a dehiscent wound, a delayed or incompletely healing wound, a chronic wound, a vasculitic ulcer, a venous ulcer or a venous stasis ulcer, an arterial ulcer, a pressure ulcer or a decubitus ulcer, a diabetic ulcer, and a skin ulcer resulting from trauma, or a skin ulcer resulting from a burn.
5. A method according to claim 1 wherein the subject is diabetic.
6. A method according to claim 1 wherein the subject is a human.
7. A method according to claim 1 wherein the subject is a non-human animal, optionally a horse, a dog or a cat.
8. A method according to claim 1 , wherein the anti-connexin 43 polynucleotide is administered in an amount ranging from about 1 to about 100 μg per square centimeter of wound size.
9. A method according to claim 8 wherein the administration of said anti-connexin 43 polynucleotide is repeated.
10. A method according to claim 8 wherein the administration of said anti-connexin 43 polynucleotide is repeated about once per week, whereby wound healing is promoted.
11. A method of treating a subject having a delayed healing, incompletely healing, or chronic wound which comprises administration to the wound of an article of manufacture comprising a connexin 43 antisense polynucleotide present at a concentration from 1.0 to about 40.0 milligrams per milliliter whereby connexin 43 expression is downregulated over a sustained period of time.
12. A method according to claim 11 wherein connexin 43 expression is downregulated for at least about 0.5 hours, at least about 1-2 hours, at least about 2-4 hours, at least about 4-6 hours, or at least about 6-8 hours.
13. A method of promoting wound healing in a subject having a delayed healing or chronic wound which comprises administration of an article of manufacture comprising a therapeutically effective amount of a connexin 43 antisense polynucleotide present at a concentration from 1.0 to about 40.0 milligrams per milliliter to a wound area effective to increase re-epithelialization rates in the wound area.
14. A method according to claim 13 wherein the antisense polynucleotide is administered in a sustained release formulation.
15. A method according to claim 13 wherein the polynucleotide is administered for a sustained period of time.
16. A method according to claim 13 wherein the antisense polynucleotide is effective to decrease connexin 43 levels for at least about 0.5 hours, at least about 1-2 hours, at least about 2-4 hours, at least about 4-6 hours, or at least about 6-8 hours.
17. A method of promoting re-epithelialization of wounds which comprises administering to a subject having a delayed healing, incomplete healing or chronic wound a composition comprising a hydrogel and an anticonnexin 43 polynucleotide in an amount effective to promote re-epithelialization.
18. A method according to claim 17 wherein the anti-connexin 43 polynucleotide is an connexin 43 antisense polynucleotide.
19. The method of any one of claim 1 , 11 , or 17 , further comprising administration of a pharmaceutical composition comprising a connexin 31.1 antisense polynucleotide.
20. A method according to any of claim 1 , 11 or 17 wherein the antisense polynucleotide comprises a sequence selected from SEQ.ID.NOS.:1 or 2.
21. A method according to any of claim 1 , 11 or 17 wherein the antisense polynucleotide has at least about 70 percent homology with SEQ.ID.NOS.:1 or 2.
22. A method according to any of claim 1 , 11 or 17 wherein the connexin 43 antisense polynucleotide hybridizes to connexin 43 mRNA under conditions of medium to high stringency.